Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with primary lung cancer originating in the outer parts of the lung, where pre-treatment scans suggest an early stage (T1N0M0, Stage IA), including those who have developed a new lung cancer after previous lung surgery or who have more than one primary lung cancer
• Alternatively, people with a tumour that has spread to the lung from another site, where the original tumour has already been fully removed, the lung tumour is no larger than 3cm across, and there are no more than 3 tumours needing treatment
• People whose lung lesion has been assessed by the medical team as suitable for microwave ablation delivered through a bronchoscope (a thin tube passed into the airways)
• People who have been assessed as not suitable for surgery or radiotherapy, or who have chosen not to have surgery or radiotherapy, and who agree to have the bronchoscope-guided microwave ablation as their first treatment, confirmed by signing a consent form

Who may not be able to join:

• People with widespread lesions throughout both lungs, where ablation treatment would not be effective
• People whose scans within the past month show that cancer has spread to lymph nodes inside the chest, or to areas outside the lungs (unless that spread outside the lungs has already been successfully treated)
• People for whom a bronchoscopy procedure is medically not recommended, or who are unable to tolerate or cooperate with the procedure
• People with serious bleeding tendencies or blood clotting problems that cannot be corrected (confirm specific blood test thresholds with trial site)
• People with a low platelet count (below 70 × 10⁹/L), or people who have been taking blood-thinning or anti-clotting medications that have not been stopped for more than one week before the ablation procedure (a specific type of preventive blood-thinning injection may be an exception — confirm with trial site)
• People with severely reduced lung function, where lung breathing capacity is less than 40% of expected (confirm with trial site)
• People who have another cancer that has spread widely and whose expected survival is less than three months
• People in generally poor health, including those with widespread cancer spread, severe infection, high fever, significant unintentional weight loss and muscle wasting, serious organ problems, severe anaemia, or nutritional or metabolic issues that cannot be corrected quickly; or those with active infection or radiation-related inflammation around the lung lesion
• People with a performance status score above 2 on the ECOG scale, meaning their cancer significantly limits daily activity (confirm with trial site)
• People whose lung lesion to be treated has received radiotherapy within the past six months
• People with active hepatitis B, active hepatitis C, known HIV infection, or other active infections that the investigator considers may affect the ability to receive treatment
• People with a history of epilepsy, psychiatric conditions, or cognitive impairment
• People who have an implanted cardiac pacemaker
• People wearing metal jewellery or clothing containing metal components at the time of treatment
• Women who are pregnant or breastfeeding, and people planning to become pregnant or father a child during the study period
• People who have taken part in another interventional clinical trial within the three months before signing the consent form
• People who the investigator considers unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.